Abstract: Disclosed herein are synthesis and use of covalent inhibitors selective for Transcriptional Enhancer Factor TEF-1 (TEAD1), which can be used for treatment of cancers such as glioblastoma, gastric cancer, colorectal cancer, pancreatic ductal adenocarcinoma (PDAC), and malignant pleural mesothelioma (MPM). Further disclosed herein are pharmaceutical compositions including the TEAD1 inhibitor and methods of treating cancers using the same.

Abstract: An antenna structure and a communication device. The antenna structure includes a feeding structure and a leaky-wave antenna. The leaky-wave antenna includes a rectangular waveguide and a radiating element, and the radiating element is located on any side wall of the rectangular waveguide. The radiating element includes slot elements, and a plurality of groups of slot elements are arranged at intervals in an extension direction of the rectangular waveguide. The slot element includes a first slot and a second slot, the first slot and the second slot are arranged with an included angle, and the first slot and the second slot are arranged at intervals in the extension direction of the rectangular waveguide. The leaky-wave antenna further includes a control component connected to the radiating element.

Abstract: The present disclosure provides a profiling method based on comparative mass spectrometry analysis for identifying and quantifying the covalent interactions of electrophilic compounds with diverse proteins in complex proteomes, as well as compositions for performing the method.

Abstract: The disclosure provides novel FGFR inhibitors based on the pyridinylpyrimidine. The disclosure includes inhibitors with broad inhibitory activity against all FGFR isoforms, and inhibitors with selective inhibition against FGFR4. These novel pyridinylpyrimidine-based FGFR inhibitors, or their derivatives, have strong potential to be used to treat cancer.

Abstract: A class of compounds useful in cancer therapy having formula (I): or an optically pure stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein X is a nitrogen or an unsubstituted C1 group; Y is a nitrogen, a substituted or an unsubstituted C1 group; Z is a nitrogen, a substituted or an unsubstituted C1 group; R1 is selected from the group consisting of: wherein R4 is independently in each instance a bond, a C1-2 alkyl group; R5 is independently in each instance a hydrogen or a C1 alkyl group; D is a hydrogen or a C1 alkyl; E is a NH, oxygen, carbonyl, substituted or unsubstituted C1 alkyl; R2 is selected from the group consisting of: and; wherein R6 is selected from the group consisting of a hydrogen, a halogen, an alkyl group; and R3 is a substituted or unsubstituted C6-18 aryl group.

Abstract: The present disclosure provides a profiling method based on comparative mass spectrometry analysis for identifying and quantifying the covalent interactions of electrophilic compounds with diverse proteins in complex proteomes, as well as compositions for performing the method.

Abstract: Provided is an anti-myopia paper sheet capable of effectively preventing eyestrain during reading or writing and reducing a reflectance factor of page reflected light, belonging to the field of stationery products. A number of graphic color blocks are printed all over a printed area for writing of the paper sheet, and each graphic color block is a graphic color block combination of any two colors of light yellow, light green, or light blue. A wavelength of reflected light in the printed area ranges from 538 nm to 590 nm, the brightness ranges from 58% to 72%, and a reflectance factor at 400 nm ranges from 48% to 60%. A page in the printed area has color purity ranging from 6% to 18%. The stimulation of full-frequency light to eyes is effectively prevented, and thus the myopia prevention is achieved.

Abstract: A method includes: A first device sends a first signal to a second device, where the first signal includes a first transmit signal and a first pilot signal; the first device obtains a second signal, where the second signal includes a first self-interference signal, a second pilot signal, and a second receive signal from the second device; the first device extracts jitter information of the first self-interference signal based on the first pilot signal and the second pilot signal; the first device reconstructs a self-interference signal based on the first transmit signal and the jitter information of the first self-interference signal, to obtain a cancellation signal of the first self-interference signal; and the first device cancels the first self-interference signal from the second receive signal based on the cancellation signal of the first self-interference signal.

Abstract: Disclosed herein are synthesis and use of covalent inhibitors selective for Transcriptional Enhancer Factor TEF-1 (TEAD1), which can be used for treatment of cancers such as glioblastoma, gastric cancer, colorectal cancer, pancreatic ductal adenocarcinoma (PDAC), and malignant pleural mesothelioma (MPM). Further disclosed herein are pharmaceutical compositions including the TEAD1 inhibitor and methods of treating cancers using the same.

Abstract: The present disclosure provides compounds and compositions thereof which are useful as inhibitors of tyrosine kinase and which exhibit desirable characteristics for the same. Further disclosed herein are methods of treating cancer using these tyrosine kinase inhibitor compounds.

Abstract: The present disclosure provides a profiling method based on comparative mass spectrometry analysis for identifying and quantifying the covalent interactions of electrophilic compounds with diverse proteins in complex proteomes, as well as compositions for performing the method.

Abstract: The disclosure provides novel FGFR inhibitors based on the pyridinylpyrimidine. The disclosure includes inhibitors with broad inhibitory activity against all FGFR isoforms, and inhibitors with selective inhibition against FGFR4. These novel pyridinylpyrimidine-based FGFR inhibitors, or their derivatives, have strong potential to be used to treat cancer.

Abstract: A method includes: A first device sends a first signal to a second device, where the first signal includes a first transmit signal and a first pilot signal; the first device obtains a second signal, where the second signal includes a first self-interference signal, a second pilot signal, and a second receive signal from the second device; the first device extracts jitter information of the first self-interference signal based on the first pilot signal and the second pilot signal; the first device reconstructs a self-interference signal based on the first transmit signal and the jitter information of the first self-interference signal, to obtain a cancellation signal of the first self-interference signal; and the first device cancels the first self-interference signal from the second receive signal based on the cancellation signal of the first self-interference signal.

Abstract: Isolated non-naturally occurring, mutant-human islet amyloid polypeptides (hIAPP) are disclosed. These polypeptides can be formulated or co-formulated at physiological pH, which enable the polypeptides of the instant disclosure to be delivered to a subject having an amyloid-based disease in a single injection with an insulin agent. Methods and compositions for treating amyloid-based disease in a subject in need thereof, by administering an effective amount of an isolated, mutant-hIAPP polypeptide, including formulations or co-formulations thereof are also disclosed.

Abstract: Isolated non-naturally occurring, mutant-human islet amyloid polypeptides (hIAPP) are disclosed. These polypeptides can be formulated or co-formulated at physiological pH, which enable the polypeptides of the instant disclosure to be delivered to a subject having an amyloid-based disease in a single injection with an insulin agent. Methods and compositions for treating amyloid-based disease in a subject in need thereof, by administering an effective amount of an isolated, mutant-hIAPP polypeptide, including formulations or co-formulations thereof are also disclosed.

Abstract: Isolated non-naturally occurring, mutant-human islet amyloid polypeptides (hIAPP) are disclosed. These polypeptides can be formulated or co-formulated at physiological pH, which enable the polypeptides of the instant disclosure to be delivered to a subject having an amyloid-based disease in a single injection with an insulin agent. Methods and compositions for treating amyloid-based disease in a subject in need thereof, by administering an effective amount of an isolated, mutant-hIAPP polypeptide, including formulations or co-formulations thereof are also disclosed.

Abstract: The present invention relates to the field of network communications, and discloses a duplex mode adaptive method, including: querying the modulation mode configuration table, to obtain a maximum modulation mode of the current duplex mode and a maximum modulation mode of the non-current duplex mode; calculating maximum spectral efficiency of the current duplex mode according to the maximum modulation mode of the current duplex mode; calculating maximum spectral efficiency of the non-current duplex mode according to the maximum modulation mode of the non-current duplex mode; comparing the maximum spectral efficiency of the current duplex mode with the maximum spectral efficiency of the non-current duplex mode, and selecting a duplex mode whose spectral efficiency is greater as a next-step duplex mode; and switching a duplex mode of the wireless communications apparatus to the next-step duplex mode.

Abstract: The present disclosure provides for isolated non-naturally occurring, mutant-human IAPP polypeptides. These polypeptides can be formulated or co-formulated at physiological pH, which enable the polypeptides of the instant disclosure to be delivered to a subject having an amyloid-based disease in a single injection with an insulin agent. The present disclosure also provides methods and compositions for treating amyloid-based disease in a subject in need thereof, comprising administering an effective amount of an isolated, mutant-hIAPP polypeptide, including formulations or co-formulations thereof.